Hexamethylmelamine-A new drug with activity in solid tumors

Ronald H. Blum, Robert B. Livingston, Stephen K. Carter

Research output: Contribution to journalArticlepeer-review

65 Scopus citations


Hexamethylmelamine (NSC 13875) is a iriazine that has completed phase I-II trials under the sponsorship of the Division of Cancer Treatment, National Cancer Institute. It was selected for clinical trial based on superior activity against the Walker 256 carcinosarcoma. In the clinical trials reported, the dose schedules used were 4-15 mg/kd/d for 21-90 days. Dose limiting toxicity was gastrointestinal. Also seen were leukopenia, thrombocylopenia, and central nervous system toxicity. The overall response rate in 784 evaluable patients was 17%. Greater than 20% response rates were seen in the following tumor types: small cell (oat) carcinoma of the lung, ovarian adenocarcinoma, lymphoma, and breast cancer. Further controlled clinical trials in certain tumor types are warranted.

Original languageEnglish (US)
Pages (from-to)195-202
Number of pages8
JournalEuropean Journal of Cancer (1965)
Issue number3
StatePublished - Mar 1973
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Hexamethylmelamine-A new drug with activity in solid tumors'. Together they form a unique fingerprint.

Cite this